The Leukemia & Lymphoma Society (LLS), a global organisation involved in the fight against cancer, along with valued partners, has launched its LLS COVID-19 Patient Financial Aid Program to help as many blood cancer patients as possible during the COVID-19 crisis, it was reported on Wednesday.
The program is to commence immediately and will grant USD250 to eligible patients struggling with the economic hardship presented by the pandemic.
The LLS COVID-19 Patient Financial Aid Program is one of many services provided by the LLS for patients, including the The Leukemia & Lymphoma Society Co-Pay Assistance Program, Patient Aid, Susan Lang Pay-It-Forward Patient Travel Assistance Program and Urgent Need Program. It will also offer free clinical trial navigation guidance through LLS's Clinical Trial Service Center, and its Information Resource Center provides patients and families with one-on-one support with a Blood Cancer Information Specialist at 800-955-4572.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories